Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88,860 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Anthracycline-free or short-term regimen as adjuvant chemotherapy for operable breast cancer: A phase III randomized non-inferiority trial.
Yu KD, Liu XY, Chen L, Mo M, Wu J, Liu GY, Di GH, Verschraegen C, Stover DG, Zhuang ZG, Bertucci F, Orlandi A, Wang J, Lippi G, Wu KJ, Osman MA, Fan L, Shao ZM. Yu KD, et al. Among authors: chen l. Lancet Reg Health West Pac. 2021 May 13;11:100158. doi: 10.1016/j.lanwpc.2021.100158. eCollection 2021 Jun. Lancet Reg Health West Pac. 2021. PMID: 34327363 Free PMC article.
Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.
Jiang YZ, Ge LP, Jin X, Fan L, He M, Liu Y, Chen L, Zuo WJ, Wu J, Liu GY, Di GH, Wang ZH, Yu KD, Shao ZM. Jiang YZ, et al. Among authors: chen l. Breast Cancer Res Treat. 2021 Jan;185(2):371-380. doi: 10.1007/s10549-020-05940-8. Epub 2020 Sep 25. Breast Cancer Res Treat. 2021. PMID: 32975708 Clinical Trial.
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, Yu KD, Fan L, Li JJ, Hou YF, Hu Z, Chen CM, Huang XY, Cao AY, Hu X, Zhao S, Ma XY, Xu Y, Sun XJ, Chai WJ, Guo X, Chen X, Xu Y, Zhu XY, Zou JJ, Yang WT, Wang ZH, Shao ZM. Chen L, et al. Among authors: chen cm, chen x. Clin Cancer Res. 2022 Jul 1;28(13):2807-2817. doi: 10.1158/1078-0432.CCR-21-4313. Clin Cancer Res. 2022. PMID: 35247906 Free PMC article.
Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.
Wu SY, Xu Y, Chen L, Fan L, Ma XY, Zhao S, Song XQ, Hu X, Yang WT, Chai WJ, Guo XM, Chen XZ, Xu YH, Zhu XY, Zou JJ, Wang ZH, Jiang YZ, Shao ZM. Wu SY, et al. Among authors: chen l, chen xz. Mol Cancer. 2022 Mar 25;21(1):84. doi: 10.1186/s12943-022-01536-6. Mol Cancer. 2022. PMID: 35337339 Free PMC article. Clinical Trial.
88,860 results
You have reached the last available page of results. Please see the User Guide for more information.